Veritas Genetics
Veritas Genetics is a private Spanish-incorporated genetic testing company that provides whole-genome and whole-exome sequencing services — organised into preventive, perinatal, and diagnostic portfolios — to consumers, clinicians, and health insurers across 11+ markets, with mandatory physician-assisted genetic counselling.
- Company typePrivate
- Founded2014
- HeadquartersDanvers, United States
- Headcount51–100
- GTM typeB2B and B2C
- OfferingServices
What Veritas Genetics does
Veritas Genetics, operating under the legal entity Veritas Intercontinental (incorporated in Madrid, Spain; CIF B88132907), is a private genetic testing company founded in 2014 that provides whole-genome and whole-exome sequencing services to consumers, clinicians, and health systems across more than 11 markets including the US, UK, Spain, Italy, Portugal, Brazil, Colombia, Ecuador, Mexico, Argentina, and the UAE. Its product portfolio is organised into four pillars — Preventive Medicine (myGenome, myGeneticRisk, myHealthScore, myPharma), Perinatal Medicine (myPrenatal, myNewborn, myBabyHealth, qCarrier, PregnancyLoss, PrenatalWES, ArrayCGH Prenatal, ThromboRisk), Diagnostic Genomics (CardioRisk, CancerRisk, GenomeDx, ExomeDx, Targeted Panels), and mandatory Genetic Counselling — with all tests requiring physician-assisted pre- and post-test counselling.
The core technology is Next-Generation Sequencing-based whole-genome and whole-exome analysis paired with advanced bioinformatics and geneticist-led variant validation, delivered through the proprietary myGenome patient-ready reporting platform. The company's commercial model is a hybrid direct-to-consumer and B2B/clinical channel: consumers request tests via the corporate website, physicians prescribe and interpret results, and genetic counsellors (in-house or partner) handle pre- and post-test engagement. In March 2026 Veritas joined an Illumina-led consortium with Fuze Health to channel preventive genomics through health-insurance plans in the US and globally, while in September 2025 it acquired Barcelona-based qGenomics to deepen clinical-diagnostics capability and European reach. Revenue is generated through one-time test fees rather than recurring subscriptions, with no publicly disclosed pricing.
Veritas Genetics firmographics
Firmographics- Name
- Veritas Genetics
- Legal name
- Veritas Intercontinental
- Website
- https://veritasgenetics.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Veritas Genetics is a private Spanish-incorporated genetic testing company that provides whole-genome and whole-exome sequencing services — organised into preventive, perinatal, and diagnostic portfolios — to consumers, clinicians, and health insurers across 11+ markets, with mandatory physician-assisted genetic counselling.
- Ownership category
- akta.pro rank
Veritas Genetics industry classification
Industry- Product category
- Genetic Testing Services
- NAICS
- Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)
- SIC
- Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Genetic & Prenatal Testing Laboratories (HLAFAMAH)
- akta.pro secondary industries
- Molecular Diagnostics & Genomics Laboratories (HLAFAMAE), Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF)
Keywords
Where Veritas Genetics is headquartered
LocationHeadquarters
- HQ city
- Danvers
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Veritas Genetics business model
Business model- GTM type
- B2B and B2C
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Genetic Testing Services: One-time genetic testing services based on whole genome and exome sequencing, with genetic counseling included. Tests include myGenome, myPrenatal, myNewborn, diagnostic panels, and pharmacogenomic testing.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels5 records
Veritas Genetics product offering
Product offeringCore offering
Veritas Genetics provides clinical genetic testing services built on whole genome and whole exome sequencing using Next Generation Sequencing technology. Its flagship myGenome platform translates complete DNA data into clinically relevant disease-risk, polygenic-risk, and pharmacogenomic reports, supported by mandatory pre- and post-test genetic counseling delivered with physician oversight across preventive, perinatal, and diagnostic use cases.
Product overview
Veritas Genetics (operating as Veritas Intercontinental) is a genetic testing company offering a unified platform of whole-genome and whole-exome sequencing services organized into four portfolio areas: Preventive Medicine, Perinatal Medicine, Diagnostic Genomics, and Genetic Counseling. The core technology is whole-genome sequencing (WGS), which generates complete DNA data that can be reanalysed over time. The flagship consumer product is myGenome, which bundles disease risk assessment, polygenic risk screening, and pharmacogenomic reporting. The perinatal portfolio spans myPrenatal (non-invasive prenatal screening), myNewborn, myBabyHealth, qCarrier, PregnancyLoss, PrenatalWES, ArrayCGH Prenatal, and ThromboRisk. The diagnostic genomics portfolio includes CardioRisk, CancerRisk, GenomeDx, ExomeDx, and Targeted Panels. Genetic Counselling is a mandatory support service across all products. The company also operates the Veritas Academy educational platform. The portfolio architecture is a single technology base (WGS/WES) with multiple disease-domain overlays, all requiring physician-assisted genetic counseling.
Differentiator
Problem solved
Functional benefit
Brands
- myGenome: Whole genome sequencing service for disease prevention and healthcare
- myGeneticRisk
- myHealthScore
- myPharma
- myPrenatal
- myNewborn
- myBabyHealth
- qCarrier
- CardioRisk
- CancerRisk
- GenomeDx
- ExomeDx
Products and services
- myGenome
Quantifiable outcome
- 17% of people have genetic variants that increase disease risk
- +5 more outcomes
Companies that use Veritas Genetics
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles3 records
Veritas Genetics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Veritas Genetics partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered flagship and core.
- Illumina Inc.flagshipIllumina and Veritas Genetics formed a strategic consortium to integrate preventive genomics into routine healthcare through health insurance programs in the United States and global markets. The partnership combines whole-genome sequencing, advanced informatics, and patient-ready genomic reporting through Veritas' myGenome platform to enable earlier identification of disease risks such as hereditary cancers and cardiometabolic conditions. The consortium also aims to generate a consented clinical-genomics dataset supporting research partnerships across the precision medicine ecosystem.
- Fuze HealthcorePart of the Illumina consortium arrangement where Fuze Health collaborates with Veritas Genetics to integrate whole-genome sequencing into preventive healthcare via insurance plans, enabling population-scale genomics programs.
- qGenomicscoreVeritas Genetics acquired qGenomics, a biotech company based in Barcelona, Spain, for an undisclosed amount. The acquisition aims to expand Veritas Genetics' capabilities in genomics diagnostics, with a focus on clinical applications and European market presence.
Scale indicators1 record
Recent moves6 records
Expansion highlights6 records
Veritas Genetics competitors and assessment
Company assessmentDirect peers
- Natera: Clinical genetic testing company specializing in reproductive health (non-invasive prenatal screening), oncology, and organ transplant monitoring. Directly comparable to Veritas's myPrenatal and broader perinatal medicine portfolio.
- Helix: Whole genome sequencing platform with a population health and health system focus. Closest technology peer to Veritas given shared WGS-based architecture and emphasis on reanalysis over time; comparable population genomics and payer strategy.
- Myriad Genetics: Established molecular diagnostics company with leading hereditary cancer testing (BRACAnalysis) and broader women's health, oncology, and mental health portfolios. Comparable to Veritas's CancerRisk and pharmacogenomic offerings, though operating at substantially larger scale as a public company.
- 23andMe: Direct-to-consumer genetic testing company offering ancestry, health risk, and carrier screening. Most directly comparable peer given Veritas's DTC motion, though 23andMe uses genotyping arrays rather than WGS, and has experienced significant business and data-privacy setbacks that frame the broader category's risk profile.
- Invitae: Clinical genetics laboratory offering hereditary cancer, reproductive, and rare disease testing across a broad test menu. Comparable to Veritas's diagnostic genomics portfolio (CancerRisk, CardioRisk, GenomeDx) and operates in similar reimbursement-driven clinical channels.
- Nebula Genomics: Direct-to-consumer whole genome sequencing company founded by George Church. Closest technology peer to Veritas given its WGS-first model, though Nebula is more consumer-focused and lacks the diagnostic/clinical breadth of Veritas's portfolio.
- GeneDx: Clinical genomics laboratory specializing in whole exome and genome sequencing for rare disease and pediatric diagnosis. Directly comparable to Veritas's GenomeDx and ExomeDx diagnostic products.
- Color Genomics: Clinical and population-scale genetic testing company offering hereditary cancer, cardiovascular, and pharmacogenomic tests with a strong employer/payer channel. Highly comparable to Veritas's preventive genomics offering, including a similar push into insurance and population health programs.
Broad incumbents
- Quest Diagnostics: Large US clinical laboratory offering an extensive genetic and molecular diagnostics menu including non-invasive prenatal screening and hereditary cancer panels. Comparable as a competing channel for physicians ordering genetic tests, though Quest operates across far broader laboratory categories.
- Laboratory Corporation of America (Labcorp): Major clinical laboratory network offering women's health, oncology, and genetic testing including through its acquisition of Invitae. Comparable as a broad clinical laboratory competitor with established physician relationships and reimbursement infrastructure that smaller genetic testing specialists must compete against.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
Veritas Genetics social profiles
Digital presenceVeritas Genetics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Veritas Genetics leadership team
Management profileNumber of profiles
Profiles4 records
Veritas Genetics subsidiaries and ownership
Company hierarchySubsidiaries1 record
Veritas Genetics funding detail
Funding detailFunding overview
Funding rounds6 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Veritas Genetics M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Veritas Genetics
What does Veritas Genetics do?
Veritas Genetics provides clinical genetic testing services built on whole genome and whole exome sequencing using Next Generation Sequencing technology. Its flagship myGenome platform translates complete DNA data into clinically relevant disease-risk, polygenic-risk, and pharmacogenomic reports, supported by mandatory pre- and post-test genetic counseling delivered with physician oversight across preventive, perinatal, and diagnostic use cases.
Is Veritas Genetics a public or private company?
Veritas Genetics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Veritas Genetics founded?
Veritas Genetics was founded in 2014. It employs 51 to 100 people.
Where is Veritas Genetics based?
Veritas Genetics is headquartered in Danvers, United States, in the North America region.
How does Veritas Genetics make money?
One revenue line is on record: genetic Testing Services.
Who are Veritas Genetics's main competitors?
Direct peers on record are Natera, Helix, Myriad Genetics, 23andMe, Invitae, Nebula Genomics, GeneDx and Color Genomics. Broad incumbents are Quest Diagnostics and Laboratory Corporation of America (Labcorp).
Does Veritas Genetics have an API?
No public API is recorded for Veritas Genetics.
What industry is Veritas Genetics in?
Veritas Genetics's product category is Genetic Testing Services. Its primary akta.pro industry code is HLAFAMAH, Genetic & Prenatal Testing Laboratories, with a secondary code of HLAFAMAE, Molecular Diagnostics & Genomics Laboratories. Its NAICS code is 621511 and its SIC code is 8071.